Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Conclusions In patients with solid tumors, ixazomib was associated with a manageable safety profile, limited antitumor activity, and evidence of downstream proteasome inhibition effects.

Source: Investigational New Drugs - March 18, 2015 Category: Drugs & Pharmacology Source Type: research